TransMedics shares jump 25% after Q3 earnings beat and raised 2026 revenue outlook

TransMedics reported third‑quarter results that topped analysts' expectations, prompting the stock to climb more than 25% on November 6. The company also lifted its 2026 revenue guidance to a range of $764 million‑$774 million, up from the prior $737 million‑$757 million. The new outlook adds $14 million of revenue from the PAD Aviation partnership.

The higher revenue forecast suggests stronger future cash flow, which could support a higher valuation for the company. Investors may price in the added $14 million from PAD Aviation when assessing the stock.

  • 1Shares rose over 25% on November 6 after the Q3 earnings release.
  • 2Q3 results exceeded expectations.
  • 32026 revenue outlook was raised to $764 million‑$774 million.
  • 4Previous 2026 revenue outlook had been $737 million‑$757 million.
  • 5The new forecast includes $14 million from PAD Aviation.

Sources